Hyderabad (Telangana) [India], Feb 19 (ANI): Dr Reddy s Laboratories said on Friday it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation of human adenoviral vector-based platform vaccine candidate Sputnik V.
As part of the review process, Dr Reddy s will present the safety profile of phase two study and interim data of phase three study which is expected to complete by February 21. The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the fight against Covid-19, said Co-chairman and Managing Director G V Prasad.
Dr Reddy s initiates process for emergency use authorisation of Sputnik V ANI | Updated: Feb 19, 2021 15:39 IST
As part of the review process, Dr Reddy s will present the safety profile of phase two study and interim data of phase three study which is expected to complete by February 21. The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the fight against Covid-19, said Co-chairman and Managing Director G V Prasad. The initiation of the emergency use authorisation process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India, he said in a statement.